Comparative Pharmacology
Head-to-head clinical analysis: ANGIOMAX versus ANGIOMAX RTU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOMAX versus ANGIOMAX RTU.
ANGIOMAX vs ANGIOMAX RTU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates, thereby inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates (fibrinogen, factor V, VIII, XIII, and protein C).
1 mg/kg intravenous bolus followed by 0.1 mg/kg/hour continuous intravenous infusion for duration of procedure; alternatively, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg/hour continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention.
1 mg/kg intravenous bolus, followed by 0.15 mg/kg/min continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention (PCI). For patients with heparin-induced thrombocytopenia (HIT) undergoing PCI, bolus 0.75 mg/kg, then 1.75 mg/kg/hour infusion for 4 hours.
None Documented
None Documented
Terminal elimination half-life: 25-30 minutes in patients with normal renal function; increased to 2-3 hours in dialysis-dependent patients
The terminal elimination half-life of bivalirudin is approximately 25 minutes in patients with normal renal function. In patients with moderate to severe renal impairment, the half-life is prolonged (e.g., up to 1 hour in patients with creatinine clearance <30 mL/min, and up to 3-4 hours in dialysis-dependent patients). This is clinically relevant for dosing adjustments and monitoring of anticoagulation.
Renal: ~90% unchanged; biliary/fecal: negligible (<1%)
Bivalirudin is cleared by a combination of renal elimination (approximately 20% unchanged in urine) and proteolytic cleavage (hepatic metabolism and other proteases). Renal clearance accounts for about 20% of total clearance. Fecal excretion is negligible (<1%).
Category C
Category C
Anticoagulant
Anticoagulant